Clinical trials: Intraperitoneal Paclitaxel
- Condition Intraperitoneal Paclitaxel
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Ovarian Carcinoma
Phase II Study of Intraperitoneal NanoPac® in Patients With Ovarian Cancer
This study will evaluate NanoPac® administered intraperitoneally (IP) immediately post-cytoreductive surgery, followed by standard of care (SOC) intravenous (IV) chemotherapy, in women with ovarian cancer.
- Trial name
- NCT03029585
- Testing
- NanoPac® 100 mg/m2, NanoPac® 200 mg/m2, NanoPac® 300 mg/m2
- Where
- 7 sites in United States
- Volunteers
- 10 people
- Sponsor
- NanOlogy, LLC